April 25, 2005
Couture for Hope
With Guest Designer Carolina Herrera
Red Sox Wives Kathryn Nixon and Karen Varitek join internationally renowned designer Carolina Herrera for two fashionably fun events in support of the Women's Cancers Program at Dana-Farber.
Couture for Hope Dinner for Carolina Herrera
What:
Trot and Kathryn Nixon and Jason and Karen Varitek host an intimate seated dinner to welcome Carolina Herrera to Boston.
Who:
Carolina Herrera
Trot Nixon and his wife Kathryn
Jason Varitek and his wife Karen
When/Where:
Thursday, May 19
The State Room, Sixty State Street, 33rd Floor, Boston
Begins 7:00 p.m.
Couture for Hope Luncheon and Runway Fashion Show
What:
Neiman Marcus presents an elegant luncheon and runway fashion preview of The Carolina Herrera Collection for Fall 2005. Guests will also share stories of survival and hope in the quest to cure women's cancers.
Who:
Carolina Herrera
Co-chairs: Kathryn Nixon, Karen Varitek, Deborah First and
Patricia Franchi Flaherty
Emcee: Joyce Kulhawik, CBS4 Arts and Entertainment Anchor
When/Where:
Friday, May 20
Hyatt Regency Boston, Grand Ballroom
One Avenue de Lafayette, Boston
11:30 a.m. – 2:00 p.m.
Couture for Hope Details
How:
Tickets to the dinner are $1,000 per person. Seats for the luncheon fashion show are $350 and $500. Visit www.jimmyfund.org/fashion for more information. Tickets may be purchased by calling Sarah Curtis at 617.632.5091.
Interviews:
Ms. Herrera is available for a limited number of media interviews while she is in Boston. Please call Karen Cummings at 617.632.5675 to request an interview. Photographers are welcome at both events.
To Benefit:
Women's Cancers Program at Dana-Farber Cancer Institute provides the highest level of patient-focused care for women with all types of breast and gynecological cancers and ensures the best possible quality of life during and following treatment. In its 11th year, Dana-Farber's innovative Women's Cancers Program also conducts research to advance the understanding, prevention, early detection, and treatment of women's cancers to benefit current patients as well as future generations of women.
